Employees: 11-50
Total raised: $17.7M
Founded date: 2004
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.07.2022 | - | $15.9M | - |
| 26.04.2016 | Series A | $1.8M | - |
Mentions in press and media 15
| Date | Title | Description |
| 05.11.2024 | BioFactura Receives $7.8 Million in Funding for Contract Options for its Smallpox Biodefense Therapeutic | BioFactura BioFactura advances its critical Smallpox countermeasure in preparation for a first-in-human Phase 1 clinical trial FREDERICK, Md., Nov. 5, 2024 /PRNewswire-PRWeb/ -- BioFactura, Inc. recently announced contract option activation... |
| 20.03.2024 | Biofactura, Inc. Expands presence at Riverside Tech Park in Frederick, Maryland to 17,520 Square Feet | BioFactura Biotechnology company consolidates operations in business community and expects to employ over 50 engineers, scientists, quality-control professionals, and related positions FREDERICK, Md., March 20, 2024 /PRNewswire-PRWeb/ -- Bi... |
| 11.09.2023 | BioFactura, Inc. publishes Phase 1 data on its Ustekinumab biosimilar | BioFactura BioFactura, Inc. announced the publication of the phase 1 study for BFI-751, a biosimilar candidate to Stelara (ustekinumab) in the peer reviewed journal, Clinical Pharmacology in Drug Development FREDERICK, Md., Sept. 11, 2023 /... |
| 10.07.2023 | BioFactura and CuraTeQ Sign Exclusive License for BFI-751—A Biosimilar to Stelara | BioFactura Jeffrey N Hausfeld, MD, MBA., Chairman and Chief Medical Officer of BioFactura, stated, "We are proud to partner with CuraTeQ to bring BioFactura's high quality biosimilar of Ustekinumab to the global marketplace in order to... |
| 14.10.2022 | BioFactura’s BFI-751, a Biosimilar Ustekinumab, Demonstrates Pharmacokinetic (PK) Bioequivalence to Stelara® in Phase 1 Study | "Meeting the primary endpoint of clinical bioequivalence in this trial, along with our bioanalytical comparative data, puts BFI-751 on the way to regulatory approval and commercial launch”, Jeffrey N. Hausfeld MD, MBA FREDERICK, Md. (P... |
| 13.10.2022 | BioFactura’s Biosimilar Ustekinumab, Demonstrates Pharmacokinetic (PK) Bioequivalence to Stelara® in Phase 1 Study | • Phase 1 clinical study demonstrated PK bioequivalence and comparable safety and immunogenicity profiles between BFI-751 and reference Stelara®. meeting the primary endpoint of clinical bioequivalence in this trial, along with our bioanaly... |
| 18.07.2022 | BioFactura Announces Activation of a $15.9M Contract Option for its Smallpox Biodefense Therapeutic | BioFactura today announced its second contract option activation of $15.9 million from the Biomedical Advanced Research and Development Authority (BARDA) BioFactura is proud to be part of this collaborative partnership with BARDA in order t... |
| 15.07.2022 | BioFactura Announces Activation of a $15.9M Contract Option for its Smallpox Biodefense Therapeutic | “This funding confirms BARDA’s continued commitment to support development of this important product." - Dr. Darryl Sampey, President and CEO, BioFactura FREDERICK, Md. (PRWEB) July 15, 2022 BioFactura today announced its second contra... |
| 19.02.2021 | BioFactura Funded $13 Million Contract Option for its Smallpox Biodefense Therapeutic | Dr. Darryl Sampey, President and CEO of BioFactura, stated, “Funding of our first option confirms the commitment of BARDA to support development of this important product. We look forward to continuing our close collaboration with BARDA as ... |
| 15.03.2017 | Notes on a pair of recent Maryland moves | The area around Columbia and Annapolis Junction along Route 32 is home to lots of tech talent, and it just picked up a couple more companies. On Monday, cybersecurity company Anchor Technologies announced a move from Annapolis to Columbia. ... |
Show more